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The pseudophosphatase MK-STYX interacts with G3BP and decreases
stress granule formation
Shanta´ D. HINTON*†, Michael P. MYERS*1, Vincent R. ROGGERO‡, Lizabeth A. ALLISON‡ and Nicholas K. TONKS*2
*Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, U.S.A., †Department of Biological Sciences, 101 Dupont Hall, Hampton University, Hampton,
VA 23668, U.S.A., and ‡Department of Biology, 3030 Integrated Science Center, College of William and Mary, Williamsburg, VA 23187, U.S.A.
MK-STYX [MAPK (mitogen-activated protein kinase)
phospho-serine/threonine/tyrosine-binding protein] is a pseudo-
phosphatase member of the dual-specificity phosphatase
subfamily of the PTPs (protein tyrosine phosphatases). MK-
STYX is catalytically inactive due to the absence of two
amino acids from the signature motif that are essential for
phosphatase activity. The nucleophilic cysteine residue and
the adjacent histidine residue, which are conserved in all
active dual-specificity phosphatases, are replaced by serine and
phenylalanine residues respectively in MK-STYX. Mutations
to introduce histidine and cysteine residues into the active site
of MK-STYX generated an active phosphatase. Using MS,
we identified G3BP1 [Ras-GAP (GTPase-activating protein)
SH3 (Src homology 3) domain-binding protein-1], a regulator
of Ras signalling, as a binding partner of MK-STYX. We
observed that G3BP1 bound to native MK-STYX; however,
binding to the mutant catalytically active form of MK-STYX
was dramatically reduced. G3BP1 is also an RNA-binding
protein with endoribonuclease activity that is recruited to
‘stress granules’ after stress stimuli. Stress granules are large
subcellular structures that serve as sites of mRNA sorting, in
which untranslated mRNAs accumulate. We have shown that
expression of MK-STYX inhibited stress granule formation
induced either by aresenite or expression of G3BP itself; however,
the catalytically active mutant MK-STYX was impaired in its
ability to inhibit G3BP-induced stress granule assembly. These
results reveal a novel facet of the function of a member of the PTP
family, illustrating a role for MK-STYX in regulating the ability
of G3BP1 to integrate changes in growth-factor stimulation
and environmental stress with the regulation of protein
synthesis.
Key words: dual-specificity phosphatase, mitogen-activated pro-
tein kinase serine-, threonine- and tyrosine-specific phosphatase
(MK-STYX), pseudophosphatase, Ras-GTPase-activating pro-
tein Src-homology-3-domain-binding protein-1 (G3BP1), stress
granule.
INTRODUCTION
A crucial aspect of signal transduction is the organization of
networks of protein–protein interactions, which is facilitated by
reversible protein phosphorylation, mediated by protein kinases
and phosphatases. Whereas the kinases have been implicated in
controlling the amplitude of a signalling response, phosphatases
are thought to play a greater role in controlling the rate and
duration of the response [1,2]. Thus the co-ordinated and com-
peting activities of kinases and phosphatases are important for
determining signalling outcome. Furthermore, disruption of the
normal patterns of protein phosphorylation results in aberrant
regulation of signal transduction and this has been implicated in
the aetiology of a variety of major human diseases, including
cancer, diabetes, inflammation and neurodegeneration.
Unlike the protein kinases, which are derived from a common
ancestor, the protein phosphatases have evolved in separate
families that are structurally and mechanistically distinct. PTPs
(protein tyrosine phosphatases), which are defined by the active-
site signature motif HC(X)5R, are divided into the classical pTyr
(phosphotyrosine)-specific phosphatases and the DSPs (dual-
specificity phosphatases) [3]. In general, they share the same
catalytic mechanism, but the conformation of the DSP active
site allows them to accommodate pSer (phosphoserine)/pThr
(phosphothreonine) residues, as well as pTyr residues in proteins.
Nonetheless, in terms of physiological function, the ‘DSPs’ may
actually show preference for either pTyr or pSer/pThr residues
in vivo. Some even target non-protein substrates, such as inositol
phospholipids and RNA. It is now apparent that the PTPs do
not simply function as passive antagonists of the PTKs (protein
tyrosine kinases), but rather are critical regulators of signalling
in their own right and have the capacity to act both positively
and negatively in the control of signal transduction. Furthermore,
the PTPs display exquisite substrate, and functional, specificity
in vivo. More recently, it has become apparent that within this
family there are several pesudophosphatases, which are members
that possess conserved domains with core features of a PTP, but
which lack residues that are essential for catalysis [3–5]. A similar
situation exists within the protein kinase family, such as in the
example of STRAD (Ste20-related adaptor), which is a Ste20-like
pseudokinase that regulates the function of the tumour suppressor
kinase LKB1 [6].
The prototypic pseudophosphatase STYX (phosphoserine/
threonine/tyrosine-binding protein) is catalytically inactive
Abbreviations used: CMT, Charcot–Marie–Tooth; CRHSP-24, calcium–responsive heat-stable protein with a molecular mass of 24 kDa; Cy3,
indocarbocyanine; DAPI, 4′,6-diamidino-2-phenylindole; DMEM, Dulbecco’s modified Eagle’s medium; D(U)SP, dual-specificity phosphatase; eIF,
eukaryotic translation initiation factor; FBS, fetal bovine serum; FLI1, Friend leukaemia virus integration 1; GAP, GTPase-activating protein; G3BP, Ras-
GAP SH3-domain-binding protein; GFP, green fluorescent protein; HEK-293 cell; human embryonic kidney cell; IA2, islet cell antigen 512; JAK, Janus
kinase; MAPK, mitogen-activated protein kinase; MKP, MAPK phosphatase; (MK-)STYX, (MAPK) phospho-serine/threonine/tyrosine-binding protein; MTM,
myotubularin; MTMR, MTM-related protein; NA, numerical aperture; NTF, nuclear transport factor; p, phospho-; PTK, protein tyrosine kinase; PTP, protein
tyrosine phosphatase; RPTP, receptor PTP; SH3, Src homology 3.
1 Present address: The International Centre for Genetic Engineering and Biotechnology, AREA Science Park, Padriciano 99, 34012 Trieste, Italy.
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because it features a glycine residue at the position expected for
the active-site cysteine residue [7]. In fact, a single-point mutation
that converts the glycine residue into cysteine was sufficient to
generate a mutant protein with activity similar to a bona fide DSP
[7]. It was proposed initially that STYX represented a new class of
pSer/pThr/pTyr-binding proteins, a naturally occurring example
of a substrate-trapping mutant [8,9] that functions as an antagonist
of endogenous protein phosphatases. Disruption of the STYX
gene in mice revealed an essential function in spermatogenesis;
the knockout mice were defective for sperm production [10].
STYX co-immunoprecipitates with a spermatid phosphoprotein,
CRHSP-24 (calcium-responsive heat-stable protein with a
molecular mass of 24 kDa), which is a unique RNA-binding
protein [10]. However, the molecular details of the function of this
catalytically impaired pseudophosphatase and the importance of
the association with CRHSP-24 remain to be defined.
Further examples of pseudophosphatases within the PTP family
include certain RPTPs (receptor PTPs). IA2 (islet cell antigen
512) (PTPRN) is a major auto-antigen in Type 1 diabetes [11].
It contains a single PTP domain that adopts the structure of a
classical PTP fold [12,13]; however, there are substitutions of
at least three catalytically essential residues in the PTP domain
of IA2. Back-mutation of these residues to the consensus found
in an active PTP domain was sufficient to restore activity [14].
The mechanism of action of IA2 remains unclear, but several
interacting proteins have been identified [15]. Unlike IA2, most
RPTPs contain a tandemly repeated arrangement of intracellular
PTP domains, in which the membrane-proximal D1 domain is
catalytically active, whereas it is the membrane-distal D2 domain
that maintains a PTP fold, but lacks critical residues for activity.
In LAR, only two point mutations are required to convert its D2
domain into an active PTP [16]. This situation is again reminiscent
of examples encountered among the protein kinases. Like the
RPTPs, the PTK JAK (Janus kinase) contains both an active
and a pseudokinase domain; the latter suppresses the activity
of the catalytic domain and is mutated in the myeloproliferative
disease polycythaemia vera, leading to enhanced JAK activity
[17]. The function of RPTP D2 domains remains unclear, although
a potential role as redox sensors has been proposed [18].
There are also further examples of pseudophosphatases within
the DSPs. In Caenorhabditis elegans, the pseudophosphatases
EGG-4 and EGG-5 bind to, and regulate signalling by, the
DYRK (dual-specificity tyrosine-phosphorylated and -regulated
kinase) family kinase MBK2 (mini brain kinase 2) [5,19].
The pseudophosphatases are most prevalent among the MTMs
(myotubularins) [20]. Of the 14 MTM genes in the human
genome, six encode pseudophosphatases [21]. It has been
shown that inactive MTMs may serve a scaffolding function,
forming complexes with the active enzymes, to regulate both
catalytic function and the subcellular location of the active
phosphatase. For example, the active enzyme MTMR2 (MTM-
related protein 2) binds the pseudophosphatase MTMR13 [22].
Inactivating mutations in MTMR2 have been associated with
type 4B CMT (Charcot–Marie–Tooth) disease, a neuropathy
characterized by abnormal nerve myelination [20]. It is interesting
to note that mutations in the pseudophosphatase MTMR13
also give rise to type 4B CMT disease [22,23], which is
consistent with the significance of the interaction between
MTMR2 and MTMR13 and the functional importance of the
pseudophosphatase component.
In the present study, we have focused on a different
pseudophosphatase, called MK-STYX [MAPK (mitogen-
activated protein kinase)-STYX] [DUSP24 (dual-specificity
phosphatase)], of which little is known except that it is highly
expressed in Ewing’s sarcoma family tumours [24]. MK-STYX
is structurally related to the DSPs, in particular the MAPK
phosphatases, which dephosphorylate both the threonine and
tyrosine residues in the activation loop of members of the MAPK
family [3,25]. MK-STYX lacks the essential catalytic cysteine
and adjacent histidine residues from the PTP signature motif.
We have demonstrated that introduction of point mutations at
the ‘active site’ of MK-STYX to generate a consensus signature
motif is sufficient to generate an active enzyme. Unexpectedly,
we observed that MK-STYX formed a complex with G3BP [Ras-
GAP (GTPase-activating protein) SH3 (Src homology 3)-domain-
binding protein]. Formation of this complex was impaired with
the catalytically active mutant form of MK-STYX. G3BP is a
phosphorylation-dependent endoribonuclease that is an effector
of stress granule formation [26]. We have demonstrated that
expression of MK-STYX significantly inhibited formation of
stress granules, which is consistent with a role as a regulator
of mRNA stability in stress-response pathways.
EXPERIMENTAL
Plasmid constructs
The N-terminal and C-terminal ends of human MK-STYX
(GenBank® accession number NM_016086.2) were flanked with
a FLAG epitope tag, and PstI and EcoRI restriction sites by PCR.
The PCR product was ligated into PstI and EcoRI sites of the
mammalian expression vector pMT2 to create pMT2-FLAG-MK-
STYX-FLAG. The QuikChangeTM Site-Directed Mutagenesis
Kit (Stratagene) was used to make the substitutions F245H
and S246C to construct the active mutant form of MK-STYX,
designated MK-STYXactive, in the expression vector pMT2-FLAG-
MK-STYXactive-FLAG. The integrity of all constructs derived from
PCR was confirmed by DNA sequencing. The G3BP–GFP (green
fluorescent protein) construct was kindly provided by Dr Jamai
Tazi (Institut de Ge´ne´tique Mole´culaire, Montpellier, France).
Cell culture and transient transfection
COS-1 cells and HEK-293 (human embryonic kidney) cells
were maintained at 37 ◦C, 5% CO2, in DMEM (Dulbecco’s
modified Eagle’s medium) supplemented with 10% FBS (fetal
bovine serum) and 1% penicillin/streptomycin (Invitrogen).
HeLa cells were maintained under similar conditions, except
they were cultured in MEM (minimal essential medium)
(Invitrogen) supplemented with 10% FBS. Transfections were
performed using FuGENETM 6 reagent (Roche Applied Science),
LipofectamineTM or LipofectamineTM 2000 reagent (Invitrogen).
Assay of protein phosphatase activity
COS-1 cells were transfected either with expression vector
for native MK-STYX (pMT2-FLAG-MK-STYX-FLAG) or
the catalytically active mutant MK-STYX (pMT2-FLAG-
MK-STYXactive-FLAG). Post-transfection (48 h), cells were
lysed and MK-STYX proteins were immunoprecipitated using
anti-FLAG antibodies (Sigma). Phosphatase activity in the
immunoprecipitates was assayed by incubation with 32P-labelled
poly(Glu-Tyr) as the substrate (5 mM pTyr-protein) at 30 ◦C in
25 mM imidazole (pH 7.2), 0.1 mg/ml BSA and 1 mM DTT
(dithiothreitol). Poly(Glu-Tyr) (4:1) (Sigma) was phosphorylated
with b-IRK (baculovirus insulin receptor kinase) in the presence
of [γ -32P]ATP [27].
Metabolic labelling and MS
Post-transfection (48 h), COS-1 cells were incubated for 30 min
in DMEM minus methionine (Invitrogen), supplemented with
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10% dialysed FBS and 1:100 L-glutamine. Subsequently, cells
were incubated for 3 h in medium containing 0.15 mCi of
35S-labelled methionine, and tagged MK-STYX proteins were
immunoprecipitated from cell lysates with anti-FLAG antibodies
(Sigma). Samples were analysed by SDS/PAGE (10% gels) and
autoradiography, or by MS. For MS, immunoprecipitates were
incubated with EZviewTM Red ANTI-FLAG® M2 Affinity Gel
(Sigma). The samples were trypsinized from EZviewTM Red
ANTI-FLAG® M2 Affinity Gel (Sigma), and analysed by LC-
MS/MS (liquid chromatography–tandem MS).
Immunoprecipitation and immunoblotting
Post-transfection (48 h), HEK-293 cells were harvested in lysis
buffer [50 mM Hepes, pH 7.2, 150 mM NaCl, 1 mM sodium
vanadate, 10% glycerol, 10 mM NaF, 1% Nonidet P-40
Alternative (Calbiochem), 1 mM PMSF, 1 mM benzamidine,
5 mg/ml aprotinin and 5 mg/ml leupeptin]. Lysates were
centrifuged at 14000 g for 10 min, and the supernatant protein
concentration was determined with the Bradford reagent. Lysates
were resolved by SDS/PAGE (10% gels) and transferred on to a
PVDF membrane (GE Healthcare) for immunoblot analysis with
anti-FLAG (Sigma) and anti-G3BP (BD Bioscience) antibodies,
followed by chemiluminescent detection. X-ray films were
quantified by scanning densitometry using ImageJ software
(National Institutes of Health). For immunoprecipitation, the
lysates were pre-cleared, then incubated with anti-FLAG or anti-
G3BP antibody for 1 h at 4 ◦C. Samples were washed three
times in lysis buffer and boiled in Laemmli sample buffer. To
determine G3BP expression levels by immunoblotting, HeLa cell
lysates were prepared 24 h post-transfection and replicate blots
were probed with anti-FLAG, anti-G3BP or anti-β-tubulin (1:200
dilution) (Santa Cruz Biotechnology) antibodies.
Transient transfection and cell imaging
For immunofluorescence, HeLa cells were grown to 80–90%
confluence and 2 × 105 cells were plated on to coverslips in
six-well dishes (Nunc). Post-plating (24 h), cells at 40–60%
confluence were transfected with 2 mg of G3BP–GFP, pMT2,
or wild-type or mutant FLAG-tagged MK-STYX expression
plasmid DNA and 4 ml of LipofectamineTM 2000 reagent per
well, according to the manufacturer’s protocol. The medium
was replaced with fresh medium at least 4 h before fixation
and staining. Post-transfection (24 h), cells were washed with
PBS, fixed with 3.7% formaldehyde and permeabilized
with 0.2% Triton X-100. The coverslips were mounted on
to a slide using GelMount containing DAPI (4′,6-diamidino-2-
phenylindole; 0.5 mg/ml; Sigma). Expression of FLAG-tagged
MK-STYX was confirmed by immunofluorescence.
For experiments examining the effect of MK-STYX on stress-
induced stress granule formation, at 23 h post-transfection, HeLa
cells were treated with 500 μM sodium arsenite (Sigma) for 1 h,
then processed as above. To visualize stress granule formation,
endogenous G3BP was used as the marker and visualized
with anti-G3BP (1:100 dilution) and Cy3 (indocarbocyanine)-
conjugated goat anti-mouse (1:200; Zymed Laboratories)
antibodies.
Counting and image collection were performed on either of two
microscopes. For some analyses, an inverted Nikon ECLIPSE
TE 2000-E fluorescence microscope, with a Nikon Ultraviolet
Excitation UV-2E/C filter block for DAPI visualization, and a
Blue Excitation B-2E/C filter block for G3BP–GFP visualization,
were used with a Nikon Plan Apo 40 × /0.95 NA (numerical
aperture) objective. A CoolSNAP HQ2 CCD (charge-coupled-
device) camera (Photometrics) and NIS-Elements AR software
(Nikon) were used for image acquisition and primary image
processing. For other analyses, an Olympus BX60 microscope
with U-MNU filter cube for DAPI and Omega Optical XF100-2
for GFP were used with an Olympus 40XUPlanFL 40 × /0.75
NA objective. A Cooke SensiCamQE camera and IPlab software
(BD Biosciences Bioimaging) were used for image acquisition
and primary image processing. ImageJ and Adobe Photoshop
CS3/IllustratorCS3 were also used for any secondary image
processing.
Approx. 400 cells were scored per treatment. Samples
were scored blind with regard to treatment and were scored
independently by two different individuals. Cells were scored in
three categories: no stress granules, intermediate stress granules
or complete stress granules. Intermediate stress granules were
characterized as smaller granules dispersed throughout the
cytoplasm. Complete stress granules were characterized as large
granule aggregates that formed around the nucleus.
RESULTS
Pseudophosphatase MK-STYX can be converted into a catalytically
active phosphatase
Database analysis was used to construct and clone a full-length
cDNA encoding the protein MK-STYX, which is the product
of the DUSP24 gene. Full-length MK-STYX displays homology
with the MKPs (MAPK phosphatases), such as MKP1 [3,25].
The consensus active-site signature motif for members of the PTP
family is [I/V]HCXXGXXR[S/T], in which the residues in bold
play critical roles in catalysis. In the catalytically functional DSP
MKP1, this motif is VHCQAGISRS, whereas in MK-STYX the
equivalent sequence is IFSTQGISRS. In the light of the absence of
the adjacent histidine and cysteine residues in the signature motif,
it would be anticipated that wild-type MK-STYX would have lim-
ited catalytic competence. This was confirmed in assays of activity
in immunoprecipitates of MK-STYX from transiently transfected
COS-1 cells overexpressing the protein (Figure 1). To test whether
a catalytically competent form of MK-STYX could be generated,
we altered its signature motif by site-directed mutagenesis to con-
vert Phe-245 and Ser-246 into the histidine and cysteine residues
respectively, which are characteristic of the signature motif of
an active PTP family member. These changes were sufficient to
generate a catalytically functional mutant form of MK-STYX that
recognized 32P-labelled poly(Glu-Tyr) as a substrate (Figure 1).
Identification of MK-STYX-binding proteins
Of the pseudophosphatase members of the PTP family studied
to date, a consistent theme is the functional importance of
protein–protein interactions. In order to gain insights into the
function of MK-STYX, we initiated a search for potential
binding partners. We transfected COS-1 cells with expression
vectors for either FLAG-tagged MK-STYX or the MK-STYXactive
mutant protein, metabolically labelled the cells with [35S]-
methionine, and immunoprecipitated the proteins with anti-FLAG
antibodies. Although there was some overlap in the binding
pattern, it was interesting to note that some proteins interacted
specifically with the wild-type catalytically suppressed form of
MK-STYX, but not the catalytically competent mutant form of the
protein (Figure 2). These differences in binding highlight
the potential functional importance of wild-type MK-STYX-
specific interacting proteins.
We analysed the MK-STYX-containing protein complexes by
MS. Our analysis confirmed the presence of MK-STYX and
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Figure 1 Conversion of MK-STYX into an active protein phosphatase
(A) The extended DSP signature motif in the pseudophosphatase MK-STYX lacks the histidine
and cysteine residues that are essential for catalysis. A mutant MK-STYX was generated to mimic
a functional DSP by substituting histidine in place of phenylalanine at residue 245 and cysteine
in place of serine at residue 246. (B) Wild-type and mutant MK-STYX were expressed in COS
cells, immunoprecipitated and assayed for phosphatase activity against poly(Glu-Tyr) (4:1) as
substrate. Three replicate experiments were performed. The results are the means +− S.E.M.
MK-STYXactive in the appropriate samples, and identified a
number of proteins as possible binding partners. In the light of the
structural features of MK-STYX, and considering the precedent
of the MTMs [21], we predicted that it might form a complex
with an active phosphatase. However, we did not detect such an
interaction. Unexpectedly, the major binding partner of wild-type
MK-STYX that we identified by MS was not a phosphatase, but an
RNA-binding protein, G3BP, which resolves as a 68 kDa protein
by SDS/PAGE [28]. In contrast, G3BP was not a significant
component of the complex that co-immunoprecipitated with MK-
STYXactive.
Figure 2 Identification of MK-STYX-binding partners
COS-1 cells were transfected with expression vectors for FLAG-tagged wild-type and active
mutant MK-STYX, metabolically labelled with [35S]methionine, and immunoprecipitated with
anti-FLAG antibodies. Binding proteins were resolved by SDS/PAGE and visualized by
autoradiography. Molecular masses are indicated on the left-hand side.
Interaction of MK-STYX with G3BP
To confirm that G3BP was a binding partner of MK-STYX,
we co-transfected HEK-293 cells with expression vectors for
GFP-tagged G3BP and either FLAG-tagged MK-STYX or MK-
STYXactive mutant. We immunoprecipitated MK-STYX with anti-
FLAG antibodies, and observed, by immunoblotting, that more
wild-type MK-STYX co-precipitated with G3BP than the MK-
STYXactive mutant when they were expressed at similar levels
(Figure 3A). This confirms the observation in our MS analysis
Figure 3 Interaction of G3BP1 and MK-STYX
HEK-293 cells were co-transfected with expression vectors for FLAG-tagged MK-STYX, mutant active MK-STYX or empty vector pMT2, and G3BP–GFP or vector pEGFP. (A) MK-STYX was
immunoprecipitated (IP) from cell lysates with anti-FLAG antibodies, and (B) G3BP1 was immunoprecipitated from cell lysates with anti-G3BP antibodies, in each case followed by immunoblotting
(IB) with anti-FLAG and anti-G3BP antibodies to investigate the extent of binding. Similar results were obtained from multiple replicate experiments.
c© The Authors Journal compilation c© 2010 Biochemical Society
MK-STYX interacts with G3BP 353
Figure 4 Inhibition of arsenite-induced stress granule formation by MK-STYX
Representative examples are presented to illustrate the subcellular distribution of endogenous G3BP1 without arsenite treatment (A) or following stimulation with 500 μM sodium arsenite
(B) in the absence (No Treatment) or presence of MK-STYX. Cells were fixed, stained with anti-G3BP and Cy3-conjugated goat anti-mouse antibodies and DAPI, and analysed 24 h post-transfection
for arsenite-induced stress granule formation by fluorescence microscopy. Merged images show the location of endogenous G3BP (red) relative to the DAPI-stained nucleus (blue). Scale bar, 10 μm.
(C) Cells were scored for the presence and absence of stress granules. Three replicate experiments were performed (n = 100 cells for each experiment); the results are the means +− S.E.M.
(Figure 2). The preference for interaction between G3BP and
wild-type MK-STYX, rather than MK-STYXactive mutant, was also
observed in the reciprocal experiment in which we immunoprecip-
itated with anti-G3BP antibodies (Figure 3B) and immunoblotted
for the presence of MK-STYX. Taken together, these experiments
confirm that MK-STYX and G3BP were binding partners in a cel-
lular context and, furthermore, that the interaction was disrupted
by mutation to convert MK-STYX into an active phosphatase.
Expression of MK-STYX decreased stress granule formation
The assembly of stress granules is triggered following stimulation
of cells with arsenite [29]. This process can be visualized by
the change in intracellular localization of endogenous G3BP,
from a diffuse distribution throughout the cytoplasm to the large
stress granule structures. In order to test whether MK-STYX
could affect this process, we compared the effects of arsenite
on localization of endogenous G3BP in HeLa cells transfected
before and after ectopic expression of MK-STYX. These cells
were chosen both to avoid any cell line bias in our present study
of the interaction and because they had been used previously in
the study of G3BP [32]. The expression of endogenous G3BP1
was visualized by staining with anti-G3BP1 and Cy3-conjugated
secondary antibody and analysed by fluorescence microscopy
(Figure 4). Exposure to arsenite induced stress granule formation
in approx. 60% of non-transfected cells, whereas expression
of MK-STYX resulted in a dramatic decrease in stress granule
formation; only approx. 18% of HeLa cells transfected with
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the MK-STYX expression plasmid formed stress granules
(Figure 4).
Stress granule formation has also been shown to be induced by
overexpression of G3BP alone [29]. Therefore we tested whether
expression of MK-STYX affected stress granule induction by
G3BP. To this end, we co-transfected GFP-tagged G3BP with
FLAG-tagged MK-STYX or MK-STYXactive mutant in HeLa cells.
The expression of G3BP–GFP was analysed by fluorescence
microscopy and cells were scored for stress granule formation
(Figure 5). Three categories were established: no stress granules,
complete stress granules (granules are large and perinuclear)
and intermediate stress granules (smaller aggregates dispersed
throughout the cytoplasm) (Figure 5A). Overexpression of G3BP
in HeLa cells induced stress granules in approx. 50% of
transfected cells (Figure 5B). Strikingly, in cells co-transfected
with the G3BP and MK-STYX expression plasmids only approx.
20% of transfected cells formed stress granules, suggesting that
expression of MK-STYX inhibited stress granule assembly. One
possible explanation for this reduced stress granule formation is
that expression of MK-STYX somehow suppressed expression
of G3BP. However, there was no significant difference in the
expression levels of G3BP when transfected alone or together
with either the empty vector or the expression vector for MK-
STYX (Figure 5C). There was an intermediate effect of expression
of MK-STYXactive mutant, in which approx. 37% of cells
co-transfected with G3BP and MK-STYXactive displayed stress
granules (Figure 5B). Thus the production of an enzymatically
active form of MK-STYX not only impaired the interaction
with G3BP, but also attenuated its inhibitory effect on stress
granule formation. Interestingly, cells expressing the MK-
STYXactive mutant displayed more intermediate stress granules
(smaller aggregates) compared with those expressing G3BP alone
(Figure 5A), suggesting that the catalytically active form of MK-
STYX slowed the process of stress granule formation, but did not
completely repress assembly.
DISCUSSION
Several pseudophosphases have been identified within the PTP
family. Their sequences suggest that they will adopt a PTP fold,
but residues that are essential for catalysis are missing and
therefore these members of the PTP family will lack intrinsic
phosphatase activity [3,5]. Investigations into the mechanism
by which these pseudophosphatases affect signalling pathways
have highlighted the importance of protein–protein interactions.
In the present paper, we report a novel interaction between the
pseudophosphatase MK-STYX and G3BP, a regulator of Ras
function and stress granule assembly. G3BP is an RNA-binding
protein, presenting an interesting symmetry between MK-STYX
and the prototypic pseudophosphatase STYX, which interacts
with the spermatid RNA-binding protein CRHSP-24 [10]. We
have demonstrated that the introduction of two point mutations in
the signature motif of MK-STYX was sufficient to convert it into
an active phosphatase. Interestingly, G3BP bound preferentially
to the native phosphatase-dead form of MK-STYX. Furthermore,
this interaction significantly reduced the formation of stress
granules induced either by arsenite treatment or by expression
of G3BP.
G3BP1 is a member of a small family of three ubiquitously
expressed proteins, derived from two distinct genes in humans.
The second member, G3BP2, exists in two differentially spliced
forms [26]. The N-terminus of the G3BPs is characterized by
the presence of a NTF (nuclear transport factor) 2-like domain
and a segment rich in acidic residues. The central segment
contains proline-rich PXXP motifs, and the C-terminal portion
of the proteins is characterized by motifs associated with RNA
binding, including a canonical RNA recognition motif and an
arginine- and glycine-rich RGG box. G3BP1 is defined as
a Ras-GAP SH3-domain-binding protein, due to a Ras-GTP-
dependent interaction between the NTF2 domain of G3BP1
and the SH3 domain of GAP in proliferating cells. Interestingly,
the G3BP homologue in Drosophila, rasputin (rin), interacts
genetically with the Ras signalling pathway [30]. G3BP1 is highly
phosphorylated on multiple serine residues in quiescent cells, but
changes in the pattern of phosphorylated residues accompany
proliferation [31]. In particular, the absence of a phosphate group
on Ser-149 in proliferating cells was shown to be dependent on
Ras-GAP and also to influence the subcellular distribution of
G3BP1 [31,32]. However, stimulation of breast cancer cells with
the EGF (epidermal growth factor) receptor ligand Heregulin
has also been shown both to induce expression and to enhance
phosphorylation of G3BP1 [33], hence the functional importance
of G3BP1 phosphorylation will require further clarification.
Expression of G3BP1 was also shown to be increased in various
tumours and to be associated with enhanced proliferation [34],
but the precise role of G3BP1 in the regulation of Ras signalling
and the control of proliferation remains unclear.
G3BPs were originally identified as displaying features of
RNA-binding proteins and are found in various messenger
ribonucleoprotein particles that regulate mRNA processing,
transport, translation and decay [26]. In particular, G3BP1 has
been identified as a component of stress granules [29]. When
cells are exposed to environmental stresses, such as heat shock,
UV irradiation, hypoxia or oxidative stress, they initiate protective
responses to enhance their survival. One of the most rapid
of these is a reversible regulation of mRNA translation to
promote expression of proteins that allow the cell to adapt
to the stress [35,36]. Formation of stress granules is triggered
by phosphorylation of eIF2a (eukaryotic translation initiation
factor 2a) under the action of several stress-activated kinases
[37], which reduces the initiation of translation. In recent years,
there has been a rapid expansion in our understanding of the
role of stress granules and G3BP in this response to cellular
stress. Stress granules are cytoplasmic storage sites for abortive
translation initiation complexes, which act as sorting stations
from which mRNAs can be routed to other sites of storage, re-
initiation of translation or degradation. They represent a complex
assembly of translation initiation factors, such as eIF3 and eIF4E,
proteins involved in translational control, such as TIA-1 (T-cell
intracellular antigen 1), and proteins implicated in RNA remod-
elling or degradation, including G3BP1 [35]. Endoribonucleases
catalyse mRNA degradation, particularly those mRNAs for which
turnover rates are regulated by extracellular stimuli [35,36]. A
unique feature of G3BP1 is that it possesses endoribonuclease
activity that is regulated by site-specific phosphorylation [32]. The
association with Ras-GAP regulates the phosphorylation status,
particularly of Ser-149, and the subcellular location of G3BP1,
which is consistent with a role for G3BP1 as a sensor that can
integrate changes in growth-factor stimulation and environmental
stress with the regulation of protein synthesis.
Not only is G3BP1 recruited to stress granules in response to
cellular stresses, such as arsenite, but also stress granule assembly
can be induced by G3BP1 overexpression alone in transiently
transfected cells [29]. Dephosphorylation of G3BP1 at Ser-149
is important in this process, as it enhances its endoribonuclease
activity, induces self aggregation and promotes stress granule
assembly. Our results have revealed a new component of this
cellular response mechanism. We have demonstrated that the
interaction of the pseudophosphatase MK-STYX with G3BP
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Figure 5 Inhibition of G3BP1-induced stress granule formation by MK-STYX
(A) Representative examples of the subcellular distribution patterns of G3BP1. HeLa cells co-transfected with expression vectors for G3BP and either wild-type or active mutant MK-STYX showed
fewer cells with fully formed stress granules. The overexpression of G3BP1 alone resulted in mostly complete perinuclear stress granule formation. Cells co-transfected with G3BP1 and the
active MK-STYX mutant accumulated smaller granules that were more dispersed throughout the cytoplasm, which may represent intermediates in stress granule formation. Merged images show
the location of GFP-tagged G3BP1 (green) relative to the DAPI-stained nucleus (blue). Scale bar, 10 μm. (B) HeLa cells were co-transfected with expression vectors for G3BP1–GFP and either
MK-STYX or MK-STYXactive mutant. Cells were analysed 24 h post-transfection for G3BP-induced stress granule formation by fluorescence microscopy, after staining with the DNA stain DAPI to
reveal the nucleus. Cells were scored for the presence or absence of stress granules. Three replicate experiments were performed (n = 400); the results are the means +− S.E.M. (C) HeLa cells were
transfected with G3BP1–GFP expression vector alone, or co-transfected with G3BP1–GFP expression vector and empty vector (pMT2), or expression vectors for wild-type or active mutant MK-STYX.
Post-transfection (24 h), cells were lysed and immunoblotted. Replicate blots were probed with anti-FLAG antibody alone, to visualize MK-STYX, or probed simultaneously with both anti-G3BP and
anti-β-tubulin antibodies. Representative immunoblots are shown.
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inhibited stress granule formation, whereas expression of the
catalytically active mutant MK-STYX led to an accumulation of
smaller intermediate-sized aggregates. The fact that MK-STYX
is a member of the PTP family of regulators of signal transduction
illustrates another potential link between extracellular signals and
stress granule assembly. However, the precise mechanism under-
lying the effects of MK-STYX remains to be defined. It is interest-
ing to note that the catalytically active mutant form of MK-STYX
neither bound to G3BP1 nor impaired stress granule formation in-
duced by expression of G3BP to the same extent as native inactive
MK-STYX, highlighting the importance of the protein–protein
interaction. It has been shown that G3BP1 is phosphorylated on
multiple sites in a cellular context [31,32]. In the light of the fact
that MK-STYX is a pseudophosphatase, and thus one aspect of
its participation in protein–protein interactions may involve the
recognition of phosphorylated amino acids in the target protein,
it will be interesting to determine the importance of Ser-149 and
the other phosphorylation sites in G3BP1 in this interaction.
Changes in expression of both MK-STYX and G3BP1 have
been linked to tumorigenesis. In Ewing’s sarcoma, a specific
chromosomal translocation that fuses the human ETS oncogene
FLI1 (Friend leukaemia virus integration 1) to the EWS gene
leads to expression of the EWS-FLI1 transcription factor,
resulting in overexpression of MK-STYX [24]. G3BP levels are
regulated by PTEN (phosphatase and tensin homologue deleted
on chromosome 10) [38] and HER2 [33]. Furthermore, expression
of G3BP1 has been implicated in the regulation of p53 [39]. It has
been reported that formation of stress granules inhibits apoptosis
in response to cellular stress by suppressing the activation of
p38 and JNK MAPKs [40]. Thus further characterization of
the functional interplay between MK-STYX and G3BP1 may
generate new insights into tumorigenesis and potential approaches
to therapy.
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